Copyright Reports & Markets. All rights reserved.

Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Anti-Platelet Drugs
    • 1.4.3 Dual Antiplatelet Therapy Drugs
    • 1.4.4 Others
  • 1.5 Market by Application
    • 1.5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Regions
    • 2.2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Peripheral Arterial Disease (PAD) Therapeutics Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Peripheral Arterial Disease (PAD) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Market Size
    • 3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
    • 3.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2019
  • 3.3 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
  • 3.4 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
  • 3.5 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)
  • 5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 6.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in North America (2019-2020)
  • 6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 7.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Europe (2019-2020)
  • 7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

8 China

  • 8.1 China Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 8.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in China (2019-2020)
  • 8.3 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 8.4 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 9.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Japan (2019-2020)
  • 9.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 9.4 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 10.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

11 India

  • 11.1 India Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 11.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in India (2019-2020)
  • 11.3 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 11.4 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
  • 12.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
  • 12.4 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 AstraZeneca Plc. (UK)
    • 13.1.1 AstraZeneca Plc. (UK) Company Details
    • 13.1.2 AstraZeneca Plc. (UK) Business Overview
    • 13.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020))
    • 13.1.5 AstraZeneca Plc. (UK) Recent Development
  • 13.2 Bayer HealthCare Pharmaceuticals (Germany)
    • 13.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
    • 13.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
    • 13.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
  • 13.3 Bristol-Myers Squibb Company (US)
    • 13.3.1 Bristol-Myers Squibb Company (US) Company Details
    • 13.3.2 Bristol-Myers Squibb Company (US) Business Overview
    • 13.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.3.5 Bristol-Myers Squibb Company (US) Recent Development
  • 13.4 Merck & Co., Inc. (US)
    • 13.4.1 Merck & Co., Inc. (US) Company Details
    • 13.4.2 Merck & Co., Inc. (US) Business Overview
    • 13.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.4.5 Merck & Co., Inc. (US) Recent Development
  • 13.5 Proteon Therapeutics, Inc. (US)
    • 13.5.1 Proteon Therapeutics, Inc. (US) Company Details
    • 13.5.2 Proteon Therapeutics, Inc. (US) Business Overview
    • 13.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.5.5 Proteon Therapeutics, Inc. (US) Recent Development
  • 13.6 Sanofi S.A. (France)
    • 13.6.1 Sanofi S.A. (France) Company Details
    • 13.6.2 Sanofi S.A. (France) Business Overview
    • 13.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.6.5 Sanofi S.A. (France) Recent Development
  • 13.7 Symic Bio, Inc. (US)
    • 13.7.1 Symic Bio, Inc. (US) Company Details
    • 13.7.2 Symic Bio, Inc. (US) Business Overview
    • 13.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.7.5 Symic Bio, Inc. (US) Recent Development
  • 13.8 TheraVasc Inc. (US)
    • 13.8.1 TheraVasc Inc. (US) Company Details
    • 13.8.2 TheraVasc Inc. (US) Business Overview
    • 13.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.8.5 TheraVasc Inc. (US) Recent Development
  • 13.9 AnGes MG, Inc. (Japan)
    • 13.9.1 AnGes MG, Inc. (Japan) Company Details
    • 13.9.2 AnGes MG, Inc. (Japan) Business Overview
    • 13.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.9.5 AnGes MG, Inc. (Japan) Recent Development
  • 13.10 Athersys, Inc. (US)
    • 13.10.1 Athersys, Inc. (US) Company Details
    • 13.10.2 Athersys, Inc. (US) Business Overview
    • 13.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 13.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 13.10.5 Athersys, Inc. (US) Recent Development
  • 13.11 Betagenon AB (Sweden)
    • 10.11.1 Betagenon AB (Sweden) Company Details
    • 10.11.2 Betagenon AB (Sweden) Business Overview
    • 10.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 10.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 10.11.5 Betagenon AB (Sweden) Recent Development
  • 13.12 miRagen Therapeutics, Inc. (US)
    • 10.12.1 miRagen Therapeutics, Inc. (US) Company Details
    • 10.12.2 miRagen Therapeutics, Inc. (US) Business Overview
    • 10.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 10.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 10.12.5 miRagen Therapeutics, Inc. (US) Recent Development
  • 13.13 Multi Gene Vascular Systems Ltd (Israel)
    • 10.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Details
    • 10.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
    • 10.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 10.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 10.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
  • 13.14 ViroMed Co. Ltd. (Korea)
    • 10.14.1 ViroMed Co. Ltd. (Korea) Company Details
    • 10.14.2 ViroMed Co. Ltd. (Korea) Business Overview
    • 10.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
    • 10.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
    • 10.14.5 ViroMed Co. Ltd. (Korea) Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Peripheral Arterial Disease (PAD) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Peripheral Arterial Disease (PAD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    AstraZeneca Plc. (UK)
    Bayer HealthCare Pharmaceuticals (Germany)
    Bristol-Myers Squibb Company (US)
    Merck & Co., Inc. (US)
    Proteon Therapeutics, Inc. (US)
    Sanofi S.A. (France)
    Symic Bio, Inc. (US)
    TheraVasc Inc. (US)
    AnGes MG, Inc. (Japan)
    Athersys, Inc. (US)
    Betagenon AB (Sweden)
    miRagen Therapeutics, Inc. (US)
    Multi Gene Vascular Systems Ltd (Israel)
    ViroMed Co. Ltd. (Korea)

    Market segment by Type, the product can be split into
    Anti-Platelet Drugs
    Dual Antiplatelet Therapy Drugs
    Others
    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now